Issue 4 - December 2022
Torin1 restores proliferation rate in Charcot-Marie- Tooth disease type 2A cells harbouring MFN2 (mitofusin 2) mutation
Objective. Mitofusin 2 (MFN2) is a mitochondrial outer membrane protein that serves primarily as a mitochondrial fusion protein but has additional functions including the tethering of mitochondrial-endoplasmic reticulum membranes, movement of mitochondria along axons, and control of the quality of mitochondria. Intriguingly, MFN2 has been referred to play a role in regulating cell pro- liferation in several cell types such that it acts as a tumour suppressor role in some forms of cancer. Previously, we found that fibroblasts derived from a Char- cot-Marie-Tooth disease type 2A (CMT2A) patient with a mutation in the GT- Pase domain of MFN2 exhibit increased proliferation and decreased autophagy.
Methods. Primary fibroblasts from a young patient affected by CMT2A harbouring c.650G > T/p.Cys217Phe mutation in the MFN2 gene were evaluated versus a healthy control to measure the proliferation rate by growth curves anal- ysis and to assess the phosphorylation of protein kinase B (AKT) at Ser473 in response to different doses of torin1, a selective catalytic ATP-competitive mam- malian target of rapamycin complex (mTOR) inhibitor, by immunoblot analysis.
Results. Herein, we demonstrated that the mammalian target of rapamy- cin complex 2 (mTORC2) is highly activated in the CMT2AMFN2 fibroblasts to promote cell growth via the AKT(Ser473) phosphorylation-mediated sig- nalling. We report that torin1 restores CMT2AMFN2 fibroblasts’ growth rate in a dose-dependent manner by decreasing AKT(Ser473) phosphorylation.
Conclusions. Overall, our study provides evidence for mTORC2, as a novel mo- lecular target that lies upstream of AKT to restore the cell proliferation rate in CMT2A fibroblasts.
Charcot-Marie-Tooth disease type 2A (CMT2A) (OMIM 609260), is an autosomal dominant inherited sensorimotor neuropathy affecting peripheral nerve axons, that has causative mutations in the mitofusin 2 (MFN2) gene located in chromosome 1 (chr1:11.998.820). This gene encodes for mitofusin 2 (MFN2) protein which is related to dynamin family GTPases. MFN2 protein has pleiotropic cellular roles, which include participation in mitochondrial fusion, mitochondria–endoplasmic reticulum tethering, mitochondrial trafficking along axons, and mitochondrial quality control 1. MFN2 is also involved in the regulation of cell survival and for this reason, it has been of interest in the cancer field 2. Cellular proliferation is closely dependent on the dynamics of mitochondria as it has been shown that high levels of mitochondrial fission are associated with active proliferation and the maintaining of mitochondrial hyper-fused morphology can regulate the cell transition from G1 to the S phase 3,4. To date, several studies in CMT2A harbouring a mono-allelic mutation in MFN2 with autosomal dominant inheritance have not been conclusive on the molecular mechanisms causing cellular alterations. Efforts have been mainly focused on respiratory chain capacity, oxidative phosphorylation 5,6, mitochondrial membrane potential 6 or mitochondrial DNA (mtDNA) content 5,7, reporting extremely variable results, whereas most of the studies about the role of MFN2 in autophagy and proliferation have been performed in tumour cells. In a previous study, we analyzed both the mitochondrial and cellular phenotypes in CMT2AMFN2 fibroblasts harbouring a monoallelic MFN2650G>T/C217F mutation in the GTPase domain 8,9, which has been classified as “likely pathogenic” from the ACMG 10. We found that CMT2AMFN2 fibroblasts presented an increase in the so-called intermediate-fragmented mitochondria; an inefficient capacity in recovering mitochondria morphology upon removal of a stressful insult; the depolarization of the mitochondrial membrane, and impaired respiration due to a significant reduction of respiratory complexes’ activities. Hence, we asked whether the presence of damaged mitochondria in CMT2AMFN2 cells would promote their clearance through the stimulation of autophagy/mitophagy. We observed a decrease in autophagosome formation leading to a reduction of the autophagy process initiation and consistent acceleration of cell division. Interestingly, we found that amongst the highest differentially expressed genes in CMT2AMFN2 fibroblasts, those controlling cell proliferation, extracellular matrix organization, and the phosphoinositide 3-kinase (PI3K)/AKT/mTOR signalling pathway were mostly represented 8,9. Based on this evidence and on the findings that mTORC2/AKT signalling pathway is highly elevated in MFN2 knocked-out cancer cells 11, we decided to verify whether mTORC2 activation was involved in the regulation of CMT2AMFN2 fibroblasts proliferation. In the present paper, we studied the AKT(Ser473) phosphorylation which is the target of the mTORC2 kinase activity 12-14 and consistently found that mTORC2-AKT signalling is activated in CMT2AMFN2 cells. We showed that treatment with torin1, a pharmacological and competitive inhibitor of mTOR, resulted in attenuation of CMT2AMFN2 fibroblasts proliferation rate, suggesting that this pathway is an important actor in CMT2A pathogenesis.
Materials and methods
Cell culture and reagents
Primary fibroblasts from a young patient affected by CMT2AMFN2 (c.650G>T/p.Cys217Phe) and a healthy control (individual with no histological or biochemical signs of mitochondrial disease), were obtained as reported in 8 after informed consent. Cells were grown in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; EuroClone, ECB7501LX10) supplemented with 10% (v/v) fetal bovine serum (FBS; EuroClone, ECS5000L), 1% (v/v) L-glutamine (E EuroClone, ECB3000D), 1% (v/v) penicillin/streptomycin (EuroClone, ECB3001D), 50μg/ml of uridine (Sigma-Aldrich, U3003), in a humidified incubator at 37°C and 5% CO2 avoiding confluence at any time. All experiments were performed on cells with similar passage numbers, ranging from 5 to 8, to avoid any artefact due to senescence. For the experiments, growing cells were plated on sterile plastic dishes or flasks and allowed to adhere for at least 24 h before use. Torin1 (MedChemExpress, USA) was used at 0.1, 0.25 and 0.5 μM for 72 h, and DMSO as a vehicle.
CMT2AMFN2 fibroblasts and control cells were seeded in 24-well plates and grown for 3 days in presence of torin1 at 0.1, 0.25 and 0.5 μM and DMSO as vehicle-only treatment conditions. Cells were harvested by trypsinization and counted by hemocytometer every 24 h from day 1 to day 3. Cells were examined with Zeiss Primovert (Zeiss, Germany). A total of three individual experiments were performed.
For each treatment, fibroblasts grown on plates were collected at the confluence and homogenized in RIPA buffer (ThermoFisher Scientific, 89900) supplemented with proteases (Cell Signaling, 5871) and phosphatase (Cell Signaling, 5870S) inhibitors. The cells were sonicated on ice and centrifuged for 10 min at 16,000×g at 4°C and the protein concentrations were determined by Bradford assay (Bio-Rad, 500-0006). Thirty μg of cell proteins were lysed and denatured in Laemmli Buffer 2X (Bio-Rad, 1610737) separated by SDS-PAGE using homemade 10% separating gel and then transferred onto PVDF membranes using a Trans-Blot transfer apparatus (Bio-Rad, California, USA). The blocking agents used were 5% nonfat dry milk before overnight incubation with anti-phospho AKT (Ser473) and anti-GAPDH and Everyblot (Bio-Rad, 12010020) before overnight incubation with anti-total AKT antibodies.
Western blots were performed using primary antibodies at the dilution of 1:1000 for anti-phospho AKT (Ser473) (Cell Signaling Technology D95), 1:2000 for anti-total AKT (Cell Signaling Technology, 40D4) and 1:15000 for anti-GAPDH (ProteinTech, 60004-1-Ig). Peroxidase Affinity Pure goat anti-mouse IgG and goat anti-rabbit IgG (Bio-Rad, 1706516 and 1706515, respectively) were added for 1 h at room temperature in the same buffer used for the primary antibodies. According to the manufacturer’s instructions, reactive bands were detected using Clarity Western ECL Substrate (Bio-Rad, 1705061). Image acquisition was performed by the LI-COR C-Digit blot scanner and densitometric analysis was performed by the Image Studio Acquisition software (Licor, Lincoln, NE).
All statistical analyses were performed using PRISM® 7.04 in analytical software (GraphPad Software Inc, San Diego, CA) and Excel (Microsoft, Inc.). Results were expressed as average values ± SD of at least three independent determinations, each performed in triplicate, if not otherwise specified using CMT2AMFN2 versus sex and age-matched control fibroblasts. Statistical significance was calculated using Student’s t parametric test set at: *p < 0.05; **p < 0.01; and ***p < 0.001; and ****p < 0.0001. A one-way analysis of variance (ANOVA) test was performed to examine the differences between more than two dependent groups. The Bonferroni correction was used for multiple comparisons.
Torin-1 restores CMT2AMFN2 fibroblasts’ growth rate by decreasing AKT(Ser473) phosphorylation in a dose-dependent way
We have already demonstrated that inhibition of AKT activity with miransertib restores cell proliferation and autophagy in CMT2AMFN2 fibroblasts’ 8,9. To further dissect the mTOR/AKT signalling pathway involvement, we used a selective catalytic ATP-competitive mTOR inhibitor, i.e., torin1, to reverse the effect of mTOR activation and prove that it is involved in the increase of cell proliferation rate of CMT2AMFN2 fibroblasts. We evaluated the antiproliferative activity of torin1 at 0.1, 0.25 and 0.5 μM for 72 h. We showed that the treatment caused a decrease in CMT2AMFN2 fibroblast growth rates compared to vehicle-only (DMSO)-treated cells as well as for the control fibroblasts according to the different inhibitor doses (Fig. 1). Since cell proliferation is controlled by mTORC2 through AKT(Ser473) phosphorylation 12-14, we evaluated mTORC2 activity by measuring the level of AKT-phosphorylation at Ser473 in CMT2AMFN2 fibroblasts. We found a very significant increase of AKT(Ser473) phosphorylation in basal conditions of CMT2AMFN2 compared to control fibroblasts. The inhibition by torin1 reduced AKT(Ser473) levels more strikingly in the mutant rather than in control fibroblasts. In detail, when we compared the levels of AKT(Ser473) at 0.5 uM torin1, we found no signal in mutant compared to control fibroblasts, despite the level of AKT(Ser473) in untreated conditions being much higher in mutant than in control. Furthermore, torin1 treatment was able to significantly reduce the abundance of AKT(Ser473) in a dose-dependent manner in CMT2AMFN2 fibroblasts (Fig. 2). The decreased cell proliferation rate reflected the different levels of AKT phosphorylation at Ser473. Taken together, these results suggested that the mTORC2 pathway is more activated in CMT2AMFN2 than in healthy control fibroblasts and highlighted the dependence of cell proliferation on this signalling pathway.
The molecular mechanism by which MFN2 mutations lead to the disease and, importantly, how this mechanism can be tackled to modify CMT2A2’s natural history is intensely studied 1,5-7,15-17. Recently, our laboratory has shown that human CMT fibroblasts harbouring heterozygous single nucleotide substitution c.650G > T in MFN2, featured increased cell proliferation and downregulation of the autophagy process initiation. The transcriptomic analysis helped us to deep into the molecular pathways responsible for the dysfunctions found in CMT2AMFN2 fibroblasts. Most of the differentially expressed genes were enriched in cell population proliferation, extracellular matrix organization, and PI3K/AKT/mTOR signalling pathway. PI3K/mTOR/AKT signalling pathway has been proven to serve an important role in regulating cell proliferation, differentiation, autophagy, and apoptosis 18-22.
Based on this evidence, we showed that AKT activation is crucial in the regulation of proliferation in CMT2AMFN2 fibroblasts. Previously, we proved that the selective pharmacological inhibition of AKT with miransertib allowed for the restoration of the autophagy and cell proliferation rate in CMT2AMFN2 cells 8,9. In the present study, we deepened the molecular mechanism responsible for the increased cell proliferation in CMT2AMFN2 fibroblasts focusing on mTORC2. We considered that mTORC2 mainly controls cell proliferation through the regulation of the phosphorylation status of AKT at Ser473 12-14. To this aim, we investigated AKT phosphorylation in CMT2AMFN2 cells, using torin1, a selective catalytic ATP-competitive mTOR inhibitor. Our results provide evidence of a strong increase of mTORC2-dependent phosphorylation of AKT(Ser473) in mutant fibroblasts. Torin1 treatment showed anti-proliferative activity in CMT2AMFN2 cells by decreasing AKT(Ser473) phosphorylation in a dose-dependent manner. We derived that in agreement with the known anabolic effects of mTORC2/AKT pathway activation, the CMT2AMFN2 fibroblasts showed a remarkable increase in cell proliferation that can be reduced by the pharmacological targeting of mTORC2. This study reinforces our previous results confirming the involvement of the mTORC2/AKT pathway in CMT2AMFN2 disease. Acting on this pathway both miransertib and torin1 produce similar effects on cell proliferation. Herein, we showed that this pathway, extensively studied in cancer, can also be important in the pathogenesis of the neurodegenerative disease. PI3K/AKT/mTOR pathway is necessary to promote growth and proliferation over differentiation of adult stem cells, neural stem cells specifically 23. It would be worth investigating the role of the PI3K/AKT/mTOR pathway in a cell system closely related to the disease, such as neuronal stem cells generated from CMT2A2 patients to understand if PI3K/AKT/mTOR signalling alterations could impact neural stem cell survival/differentiation. Overall, our results unveil mTORC2/AKT as novel potential targets that play a role in CMT2A2 pathophysiology.
In conclusion, our evidence showed that CMT2AMFN2 fibroblasts harbouring heterozygous single nucleotide substitution c.650G > T MFN2 showed increased proliferation because of mTORC2 activation. Considering that MFN2 is defined as a tumour suppressor, and based on our previous findings, we can hypothesize that MFN2 mutation may act as a dominant trait on cell proliferation, giving thus an unchecked trait on the cell division. Torin1 treatment can restore the cellular growth rates of CMT2AMFN2 fibroblasts in a dose dependent-manner acting on the AKT(Ser473) phosphorylation. Overall, these data established the dependence of cell proliferation on the mTORC2 pathway that thus represents a new potential actor in CMT2A2 pathophysiology.
We thank the patients’ associations MITOCON, UILDM (Unione Italiana Lotta alla Distrofa Muscolare), and CollaGe-Associazione-Genitori-Manzoni-Poli-Molfetta.
Conflict of interest statement
All authors have read and agreed to the published version of the manuscript. The Authors alone are responsible for the content and writing. No potential competing interest was reported by the authors.
This work was funded by REGIONE PUGLIA-MALATTIE RARE-Petruzzella, Uff. Pres.n. 246-10 ott. 2019 “Neuropatie ereditarie in Puglia: meccanismi patogenici e nuove strategie terapeutiche – NeurApulia” and by donations of Parents’, Associations (VP) and Opera Pia Foundation (PZ, AA) by the Italian Ministry of Health-Ricerca Corrente2021-5X1000 (FMS).
PZ, VP: designed the research; FMS: provided the CMT2AMFN2 fibroblasts; PZ, AA, EAP: performed the research and analyzed the data; PZ, VP: wrote the manuscript.
As reported in ref. 8, the family’s patient signed informed consent for research use of clinical data.
Figures and tables
- Filadi R, Pendin D, Pizzo P. Mitofusin 2: from functions to disease. Cell Death Dis. 2018;9. doi:https://doi.org/10.1038/s41419-017-0023-6
- Xin Y, Li J, Wu W. Mitofusin-2: a new mediator of pathological cell proliferation. Front Cell Dev Biol. 2021;9. doi:https://doi.org/10.3389/fcell.2021.647631
- Chen H, Chan D. Mitochondrial dynamics in regulating the unique phenotypes of cancer and stem cells. Cell Metabolism. 2017;26:39-48. doi:https://doi.org/10.1016/j.cmet.2017.05.016
- Mitra K, Wunder C, Roysam B. A hyperfused mitochondrial state achieved at G 1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci USA. 2009;106:11960-11965. doi:https://doi.org/10.1073/pnas.0904875106
- Amiott E, Lott P, Soto J. Mitochondrial fusion and function in Charcot-Marie-Tooth type 2A patient fibroblasts with mitofusin 2 mutations. Experimental Neurology. 2008;211:115-127. doi:https://doi.org/10.1016/j.expneurol.2008.01.010
- Loiseau D, Chevrollier A, Verny C. Mitochondrial coupling defect in Charcot-Marie-Tooth type 2A disease. Ann Neurol. 2007;61:315-323. doi:https://doi.org/10.1002/ana.21086
- Vielhaber S, Debska-Vielhaber G, Peeva V. Mitofusin 2 mutations affect mitochondrial function by mitochondrial DNA depletion. Acta Neuropathol. 2013;125:245-256. doi:https://doi.org/10.1007/s00401-012-1036-y
- Zanfardino P, Longo G, Amati A. Mitofusin 2 mutation drives cell proliferation in Charcot-Marie-Tooth 2A fibroblasts. Hum Mol Genet. Published online 2022. doi:https://doi.org/10.1093/hmg/ddac201
- Zanfardino P, Petruzzella V. Autophagy and proliferation are dysregulated in Charcot-Marie-Tooth disease type 2A cells harboring MFN2 (mitofusin 2) mutation. Autophagy Rep. 2022;1:537-541. doi:https://doi.org/10.1080/27694127.2022.2132447
- Richards S, Aziz N, Bale S. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genetics Med. 2015;17:405-424. doi:https://doi.org/10.1038/gim.2015.30
- Xu K, Chen G, Li X. MFN2 suppresses cancer progression through inhibition of mTORC2/Akt signaling. Sci Rep. 2017;7. doi:https://doi.org/10.1038/srep41718
- Saxton R, Sabatini D. MTOR Signaling in growth, metabolism, and disease. Cell. 2017;168:960-976. doi:https://doi.org/10.1016/j.cell.2017.02.004
- Sarbassov D, Guertin D, Ali S. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science. 2005;307:1098-1101. doi:https://doi.org/10.1126/science.1106148
- Hong S, Inoki K. Evaluating the m mTOR Pathway in physiological and pharmacological settings. Methods Enzymol. 2017;587:405-428. doi:https://doi.org/10.1016/bs.mie.2016.09.068
- Baloh R, Schmidt R, Pestronk A. Altered axonal mitochondrial transport in the pathogenesis of Charcot-Marie-Tooth Disease from Mitofusin 2 mutations. J Neurosci. 2007;27:422-430. doi:https://doi.org/10.1523/JNEUROSCI.4798-06.2007
- Larrea D, Pera M, Gonnelli A. MFN2 mutations in Charcot-Marie-Tooth disease alter mitochondria-associated ER membrane function but do not impair bioenergetics. Hum Mol Genet. 2019;28:1782-1800. doi:https://doi.org/10.1093/hmg/ddz008
- Rizzo F, Ronchi D, Salani S. Selective mitochondrial depletion, apoptosis resistance, and increased mitophagy in human Charcot-Marie-Tooth 2A motor neurons. Hum Mol Genet. 2016;25:4266-4281. doi:https://doi.org/10.1093/hmg/ddw258
- Zou Z, Tao T, Li H. mTOR signaling pathway and mTOR inhibitors in cancer: progress and challenges. Cell Biosci. 2020;10. doi:https://doi.org/10.1186/s13578-020-00396-1
- Martini M, De Santis M, Braccini L. PI3K/AKT signaling pathway and cancer: an updated review. Ann Med. 2014;46:372-383. doi:https://doi.org/10.3109/07853890.2014.912836
- Shi X, Wang J, Lei Y. Research progress on the PI3K/AKT signaling pathway in gynecological cancer (review). Mol Med Report. Published online 2019. doi:https://doi.org/10.3892/mmr.2019.10121
- Yazid M, Hung-Chih C. Perturbation of PI3K/Akt signaling affected autophagy modulation in dystrophin-deficient myoblasts. Cell Commun Signal. 2021;19. doi:https://doi.org/10.1186/s12964-021-00785-0
- Chadha R, Meador-Woodruff J. Downregulated AKT-mTOR signalling pathway proteins in the dorsolateral prefrontal cortex in Schizophrenia. Neuropsychopharmacol. 2020;45:1059-1067. doi:https://doi.org/10.1038/s41386-020-0614-2
- Peltier J, O’Neill A, Schaffer D. PI3K/Akt and CREB regulate adult neural hippocampal progenitor proliferation and differentiation. Devel Neurobio. 2007;67:1348-1361. doi:https://doi.org/10.1002/dneu.20506
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2023 Acta Myologica
How to Cite
- Abstract viewed - 33 times
- PDF downloaded - 14 times